Mitra Biotech is a global leader in advancing personalized cancer treatment. We are evolving the personalization of treatment selection and drug development through our phenotypic platforms that reliably predict individual response to tested treatment. Founded in 2010, Mitra is headquartered in Woburn, MA and maintains a significant research and laboratory presence in Bangalore, India. We are committed to developing new technologies that surpass existing biomarker-guided strategies for cancer treatment selection, expanding access to truly personalized medicine, and enhancing the clinical management of cancer. Our unique CANscript™ platform delivers individualized treatment response predictions to inform patient-specific cancer treatment selection and enhance drug discovery and development. Mitra partners with leading hospitals and pharmaceutical companies worldwide.